Even unprofitable businesses can yield returns for shareholders if purchased wisely. Examining LENZ Therapeutics' cash burn, it had a cash runway of 3.0 years as of September 2024, with analysts predicting cash flow breakeven in 4 years.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing